



CENTER FOR MEDICARE

DATE: July 23, 2026

TO: All Prescription Drug Plans, Medicare Advantage-Prescription Drug Plans, Section 1876 Cost Plans, Medicare-Medicaid Plans, and PACE Organizations

FROM: Vanessa S. Duran, Director
Medicare Drug Benefit and C & D Data Group

SUBJECT: Summer Update Window for CY 2027 Formularies

CMS is currently granting conditional approvals for CY 2027 formularies and contacting those organizations that still have outstanding formulary issues. We remind Part D sponsors of the importance of resolving any outstanding formulary concerns promptly.

Part D sponsors may make limited updates to formularies that are in an approved status in the Health Plan Management System (HPMS) during the summer update window, from **12:00 a.m. EDT on August 6, 2026, through 5:00 p.m. EDT on August 10, 2026**. The revised CY 2027 Formulary Reference File (FRF) and accompanying change report are now available in the CY 2027 HPMS Formulary Submission Module.

During the summer update window, Part D sponsors can make the following changes to approved CY 2027 formularies:

1. Addition of drugs new to the updated CY 2027 FRF;¹
2. Negative changes to an existing formulary drug if an equivalent generic, biosimilar, or other therapeutically similar drug is available on the FRF and the sponsor has submitted the alternative drug on the corresponding formulary file update within the same category and class, at the same or lower cost share tier, and with no more restrictive utilization management (UM) than what the sponsor applied to the existing formulary drug;
3. Negative changes made in accordance with Section 90 of the [Final Calendar Year 2026 Part D Redesign Program Instructions](#) and § 423.120(e)(2)(i); and
4. Other limited formulary enhancements (e.g., formulary additions, reduction in cost share tiers, removal of UM edits).

¹ Sponsors must add new protected class drugs on the FRF during this submission window.

We do not expect sponsors to make significant formulary enhancements or significant negative changes during this window, as the sponsor developed the Part D bid using the formulary that they initially submitted to CMS for review.

Sponsors should limit revisions of existing UM criteria to Step Therapy (ST) criteria changes that are necessary due to allowable formulary changes described in this memo. Sponsors may only update ST criteria when the addition of new drug(s) to an existing ST group description necessitates wording changes within the ST Criteria field. In this case, sponsors should submit a PA/ST Criteria Change Request File via HPMS between 12:00 a.m. EDT on July 30, 2026, and 5:00 p.m. EDT on August 5, 2026. Please refer to the HPMS Formulary Submission Module & Reports Technical Manual for detailed submission instructions:

HPMS Homepage > Plan Formularies > Formulary Submission Module > CY 2027 > Documentation > Formulary Instructions

Following the update window, Part D sponsors should check the status of formulary approvals in HPMS. CMS will enter approval of formulary updates into HPMS by September 1, 2026. If you have any questions regarding this summer update window, please email PartDFormularies@cms.hhs.gov.